You are herePharma News

Pharma News

New discovery can delay Alzheimer's development

Researchers from Michigan University have found out cellular structure called the Golgi that mysteriously becomes fragmented in all Alzheimer's patients and looks like major cause of Alzeimer's Disease (AD). this mechanism helps decode amyloid plaque formation in the brains of Alzheimer's patients—plaques that kills cells and contributes to memory loss and other Alzheimer's symptoms.
The researchers discovered the molecular process behind Golgi fragmentation, and also developed two techniques to 'rescue' the Golgi structure.

Government lifting ban from Analgin

Indian health ministry revoked the ban from Analgin, potent analgesic and antipyretic. Last year in June 2013, government issued a ban on manufacturing and selling of analgin in country because it is involved in risk to human beings and whereas safer alternatives of analgin are available. After revoking ban from pioglitazone, this is the second time when ministry has lifted ban from a drug.

U.S. FDA approval for Eliquis® (apixaban) to reduce risk of thrmobosis in Hip or Knee Replacement Surgery

Bristol-Myers Squibb Company and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) approved a Supplemental New Drug Application (sNDA) for Eliquis (apixaban) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery.

GSK marketed products Mekinist in combination with Tafinlar received FDA nod for Advanced Melanoma

FDA approved combination therapy of Mekinist (trametinib) and Tafinlar (dabrafenib) for treatment of advanced melanoma that is unresectable or metastatic. In May 2013, FDA had already approved both drugs as single agents to treat patients with unresectable or metastatic melanoma, skin cancer.

Aha Moment : NSAIDs could be used to fight drug resistant bacterias

New serendipitous discovery which may open a new concept of resisting bacteria from growing in body. Associate professor Aaron Oakley and his team reported that non-steroidal anti-inflammatory drugs (NSAIDs) are exhibit some antibacterial property and acting on DNA replication of bacteria.

Similarity in damage due to Alzheimer's Disease in Twins

Researchers found that twin pairs had similar progressions of Alzheimer’s Disease (AD) and dementia prior to death and even they also had similar combinations of pathogenesis in two or more unconnected areas of damage to the brain. This unique study was conducted by international team of researchers led by USC psychologist Margaret Gatz.

Novartis's Jakavi ® shows positive Phase III results in Polycythemia Vera

Novartis announced that Jakavi ® (ruxolitinib) showed positive reponse in compare to present therpies for Polycythemia Vera, a rare and incurable blood cancer with increase number of erythrocytes production. In phase III trial, Jakavi ® succeed to maintain hematocrit control, erythrocytes volume, without the need of phlebotomy and reducing spleen size in patients with polycythemia vera resistant to or intolerant of hydroxyurea.

Gujarat plant of Sun Pharma hit by import ban from FDA

Karkhadi (Gujarat) based plant of Sun Pharmaceuticals imposed ban by USFDA. This ban is applied on import of all drug products from this plant. This detention was carried out without physical examination of drugs because company failed to met good manufacturing practices rules, as per FDA website on Wednesday.

FDA issued warning letter against Indian based Canton Laboratories upon quality issues

During  their last investigation in April 2013 at Canton Laboratories- Vadodara,  U.S. food and Drug Administration (FDA) identified significant deviations from current good manufacturing practice (CGMP) for the manufacture of active pharmaceutical ingredients (APIs) and in view of it, FDA issued a warning letter.

Cefaly gets FDA approval for marketing - First medical device approved to prevent migraine

U.S. Food and Drug Administration allowed marketing of the first device, Cefaly-manufactured by STX-Med in Belgium, as a preventative treatment for migraine headaches. This is also the first transcutaneous electrical nerve stimulation (TENS) device specifically authorized for use prior to the onset of pain.